The global orexin receptor agonist for narcolepsy market was valued at $3.1 billion in 2025 and is projected to surge to approximately $14.8 billion by 2034, expanding at a robust compound annual growth rate (CAGR) of 17.8% during the forecast period from 2026 to 2034. This exceptional growth trajectory is primarily driven by the paradigm-shifting transition in narcolepsy treatment from symptomatic management to disease-modifying orexin replacement strategies, the commercial maturation of orexin-2 receptor agonists as first-in-class agents, and accelerating pharmaceutical investment in the central nervous system (CNS) sleep disorder space. Narcolepsy affects an estimated 1 in 2,000 individuals globally, with prevalence rates reaching approximately 3 million patients in the United States, Europe, and Japan combined, yet historically fewer than 30% of cases have been formally diagnosed and treated, indicating a vast reservoir of addressable patient population that orexin-targeted therapies are uniquely positioned to capture.
https://researchintelo.com/report/orexin-receptor-agonist-for-narcolepsy-market
https://researchintelo.com/report/orexin-receptor-agonist-for-narcolepsy-market
The global orexin receptor agonist for narcolepsy market was valued at $3.1 billion in 2025 and is projected to surge to approximately $14.8 billion by 2034, expanding at a robust compound annual growth rate (CAGR) of 17.8% during the forecast period from 2026 to 2034. This exceptional growth trajectory is primarily driven by the paradigm-shifting transition in narcolepsy treatment from symptomatic management to disease-modifying orexin replacement strategies, the commercial maturation of orexin-2 receptor agonists as first-in-class agents, and accelerating pharmaceutical investment in the central nervous system (CNS) sleep disorder space. Narcolepsy affects an estimated 1 in 2,000 individuals globally, with prevalence rates reaching approximately 3 million patients in the United States, Europe, and Japan combined, yet historically fewer than 30% of cases have been formally diagnosed and treated, indicating a vast reservoir of addressable patient population that orexin-targeted therapies are uniquely positioned to capture.
https://researchintelo.com/report/orexin-receptor-agonist-for-narcolepsy-market
·4 Views